Marco Valgimigli MD
Deputy Chief of Cardiology and Director of the Cardiovascular Research Service, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Lugano, SwitzerlandProf. Marco Valgimigli is Deputy Chief of Cardiology and Director of the Cardiovascular Research Service at Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland. He designed and conducted more than 20 investigator-initiated multicenter randomized clinical trials and served as steering or executive committee member of numerous sponsor-driven interventional studies. During the last few years, he has been task force member of multiple European Society of Cardiology (ESC) guidelines and chaired the 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) and the upcoming 2022 EAPCI/ACVC/EAPC consensus document on antithrombotic treatment strategies in patients with established coronary artery disease.
Disclosures
M.V. reports grants and/or personal fees from Astra Zeneca, Terumo, Alvimedica/CID, Abbott Vascular, Daiichi Sankyo, Bayer, CoreFLOW, Idorsia Pharmaceuticals-Ltd, Universität Basel Department Klinische Forschung, Vifor, Bristol-Myers-Squib SA, Biotronik, Boston scientific, Medtronic, Vesalio, Novartis, Chiesi, PhaseBio, outside the submitted work.
The other authors report no relationships relevant to the contents of this paper to disclose.